Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

doi:10.1158/2159-8290.CD-16-0828

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Cancer discovery - 1 Mar 2017

Anagnostou Valsamo, Smith Kellie N, Forde Patrick M, Niknafs Noushin, Bhattacharya Rohit, White James, Zhang Theresa, Adleff Vilmos, Phallen Jillian, Wali Neha, Hruban Carolyn, Guthrie Violeta B, Rodgers Kristen, Naidoo Jarushka, Kang Hyunseok, Sharfman William, Georgiades Christos, Verde Franco, Illei Peter, Li Qing Kay, Gabrielson Edward, Brock Malcolm V, Zahnow Cynthia A, Baylin Stephen B, Scharpf Robert B, Brahmer Julie R, Karchin Rachel, Pardoll Drew M, Velculescu Victor E

Abstract excerpt

Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance in patients with non-small cell lung cancer after initial response to immune checkpoint blockade with anti-PD-1 or anti-PD-1/anti-CTLA-4 antibodies. Analyses of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Cycle Checkpoints

Share to CTLA-4 Antigen

Share to Ipilimumab

Share to Janus Kinase 1

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Share to Receptors, Antigen, T-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 28031159
DOI: 10.1158/2159-8290.CD-16-0828
PMCID: PMC5733805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.PMID 28031159Read ↗

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1.Semantic proximity Read ↗

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Semantic proximity Read ↗

Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.Semantic proximity Read ↗

The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.Semantic proximity Read ↗

Clonal driver neoantigen loss under EGFR TKI and immune selection pressures.Semantic proximity Read ↗

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and ImmunotherapySemantic proximity Read ↗

Integrated modeling to implicate evolving neoantigen-T cell interplays and immunotherapy efficacy in tumorsSemantic proximity Read ↗

Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for ImmunotherapySemantic proximity Read ↗

Targeting neoantigens for cancer immunotherapy: Table 1.Semantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape.Semantic proximity Read ↗

Identification and Targeting of Mutant Peptide Neoantigens in Cancer ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.